Atomwise is a technology-driven pharmaceutical company that leverages artificial intelligence (AI) to revolutionize small molecule drug discovery. By pioneering the use of deep learning for structure-based drug design, Atomwise has developed a best-in-class AI discovery engine capable of identifying and optimizing novel chemical compounds. This innovative approach has been extensively validated, demonstrating the ability to discover compounds with therapeutic potential across a diverse range of protein types and numerous challenging targets. Atomwise is advancing a proprietary pipeline of small-molecule drug candidates, aiming to transform the drug discovery process and deliver better medicines to patients more efficiently.
Key Features and Functionality:
- AtomNet® Technology: The first deep convolutional neural network designed for drug discovery, capable of screening over 16 billion compounds in less than two days.
- Extensive Validation: Demonstrated success in over 185 projects, including a wide variety of protein types and numerous "hard-to-drug" targets.
- Collaborative Partnerships: Engaged in over 775 collaborations with more than 250 partners worldwide, addressing over 600 unique disease targets.
- Proprietary Pipeline: Developing a pipeline of small-molecule drug candidates advancing into preclinical studies.
Primary Value and Problem Solved:
Atomwise addresses the inefficiencies and limitations of traditional drug discovery methods by integrating AI and deep learning into the process. This approach enables the rapid and accurate identification of potential drug candidates, significantly reducing the time and resources required for hit discovery, lead optimization, and toxicity predictions. By overcoming physical barriers and expanding the chemical space for screening, Atomwise enhances the likelihood of discovering effective and safe therapeutics, ultimately accelerating the development of better medicines for patients.
